Last reviewed · How we verify

Zodiac Produtos Farmaceuticos S.A. — Portfolio Competitive Intelligence Brief

Zodiac Produtos Farmaceuticos S.A. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Meloxicam and Glucosamine Meloxicam and Glucosamine phase 3 NSAID + nutraceutical combination COX-2 (meloxicam); cartilage matrix precursor (glucosamine) Rheumatology / Orthopedics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Zodiac Produtos Farmaceuticos S.A.:

Cite this brief

Drug Landscape (2026). Zodiac Produtos Farmaceuticos S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zodiac-produtos-farmaceuticos-s-a. Accessed 2026-05-17.

Related